PMID- 37081687
OWN - NLM
STAT- MEDLINE
DCOM- 20231205
LR  - 20231228
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 62
IP  - 23
DP  - 2023 Dec 1
TI  - Marked Increase in Urinary C-peptide Levels after Treatment with 
      Sacubitril/Valsartan in Patients with Type 2 Diabetes Mellitus and Hypertension.
PG  - 3501-3506
LID - 10.2169/internalmedicine.1369-22 [doi]
AB  - Sacubitril/valsartan, a novel therapy in chronic heart failure (CHF), inhibits 
      the breakdown of various peptides. However, whether or not sacubitril/valsartan 
      administration affects urinary C-peptide levels is unclear. We herein report a 
      70-year-old man with type 2 diabetes mellitus (T2DM) and hypertension coexisting 
      with CHF and nephrotic syndrome. The patient's urinary C-peptide levels 
      dramatically increased after sacubitril/valsartan administration and decreased 
      after discontinuation of the drug. Furthermore, sacubitril/valsartan 
      administration to five other patients with hypertension and T2DM markedly 
      increased urinary C-peptide levels. Thus, the insulin secretory capacity of 
      patients with T2DM receiving sacubitril/valsartan may be overestimated when their 
      urinary C-peptide level is measured.
FAU - Tanji, Yasuhiro
AU  - Tanji Y
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
FAU - Sawada, Shojiro
AU  - Sawada S
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
FAU - Numahata, Takaki
AU  - Numahata T
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
FAU - Watanabe, Taichi
AU  - Watanabe T
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
FAU - Munakata, Yuichiro
AU  - Munakata Y
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
FAU - Akai, Hiroaki
AU  - Akai H
AD  - Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and 
      Pharmaceutical University, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20230421
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 17ERJ0MKGI (sacubitril)
RN  - 0 (C-Peptide)
RN  - 0 (Tetrazoles)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 80M03YXJ7I (Valsartan)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Male
MH  - Humans
MH  - Aged
MH  - C-Peptide
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Tetrazoles/therapeutic use
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Valsartan
MH  - *Hypertension/complications/drug therapy/metabolism
MH  - Biphenyl Compounds/therapeutic use
MH  - *Heart Failure/complications/drug therapy/metabolism
MH  - Drug Combinations
MH  - Stroke Volume
PMC - PMC10749805
OTO - NOTNLM
OT  - insulin secretory capacity
OT  - sacubitril/valsartan
OT  - urinary C-peptide
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2023/04/21 06:41
MHDA- 2023/12/05 12:44
PMCR- 2023/12/01
CRDT- 2023/04/21 00:04
PHST- 2023/12/05 12:44 [medline]
PHST- 2023/04/21 06:41 [pubmed]
PHST- 2023/04/21 00:04 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 10.2169/internalmedicine.1369-22 [doi]
PST - ppublish
SO  - Intern Med. 2023 Dec 1;62(23):3501-3506. doi: 10.2169/internalmedicine.1369-22. 
      Epub 2023 Apr 21.